Celestab® (Capsules) Instructions for Use
Marketing Authorization Holder
Aliym, JSC (Russia)
ATC Code
N06BX13 (Idebenone)
Active Substance
Idebenone (Rec.INN registered by WHO)
Dosage Form
| Celestab® | Capsules 45 mg: 10, 15, 20, 30, 40, 45, 60, 90, 120, or 180 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size №1, with a yellow body and cap; the capsule contents are a mixture of powder and granules from yellow to yellow-orange in color.
| 1 caps. | |
| Idebenone | 45 mg |
Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, crospovidone, povidone K30, magnesium stearate.
Composition of the capsule body and cap: titanium dioxide, quinoline yellow dye, sunset yellow FCF dye, gelatin.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (1) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.
30 pcs. – blister packs (1) – cardboard packs.
30 pcs. – blister packs (2) – cardboard packs.
30 pcs. – blister packs (3) – cardboard packs.
30 pcs. – blister packs (4) – cardboard packs.
30 pcs. – blister packs (6) – cardboard packs.
Clinical-Pharmacological Group
Nootropic drug
Pharmacotherapeutic Group
Nootropic agent
Pharmacological Action
A nootropic agent with a metabolic effect. It enhances metabolic processes in the brain by activating the synthesis of glucose and ATP, improves blood supply and oxygenation of brain tissue, and promotes the elimination of lactates; it increases the intensity and speed of neurophysiological reactions of brain structures.
By slowing down lipid peroxidation, it protects neuronal and mitochondrial membranes from damage.
Antiasthenic, psychostimulant, and antidepressant effects are evident from the first days of administration; the nootropic effect manifests after 3-4 weeks of use.
Pharmacokinetics
Absorption is rapid and high; Tmax is 4 hours. It penetrates the blood-brain barrier in significant amounts and is distributed in brain tissues.
It does not accumulate. It is excreted by the kidneys.
Indications
Psycho-organic syndrome against the background of cerebrovascular disorders and age-related involutional changes of the brain; cerebrasthenic disorders of vascular, traumatic, psychogenic (neurasthenia) etiology: memory and/or attention impairments, decreased intellectual productivity and general activity, emotional lability; asthenic and astheno-depressive syndrome, moderately expressed depressive syndrome; dizziness, tinnitus.
ICD codes
| ICD-10 code | Indication |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| F31 | Bipolar affective disorder |
| F32 | Depressive episode |
| F33 | Recurrent depressive disorder |
| F41.2 | Mixed anxiety and depressive disorder |
| F48.0 | Neurasthenia |
| H93.1 | Tinnitus (subjective) |
| I67.2 | Cerebral atherosclerosis |
| I69 | Sequelae of cerebrovascular diseases |
| R42 | Dizziness and giddiness |
| T90 | Sequelae of injuries of head |
| ICD-11 code | Indication |
| 6A60.Z | Bipolar type I disorder, unspecified |
| 6A61.Z | Bipolar type II disorder, unspecified |
| 6A6Z | Bipolar or similar disorder, unspecified |
| 6A70.Z | Single episode depressive disorder, unspecified |
| 6A71.Z | Recurrent depressive disorder, unspecified |
| 6A73 | Mixed depressive and anxiety disorder |
| 6A8Z | Affective disorders, unspecified |
| 6C9Z | Disruptive behavior or dissocial disorders, unspecified |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| BD55 | Asymptomatic stenosis of intracranial or extracranial artery |
| MB48.Z | Dizziness and giddiness, unspecified |
| MC41 | Tinnitus |
| NA0Z | Head injury, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take Celestab®orally with a full glass of water.
Administer the capsules after meals to minimize potential gastrointestinal discomfort.
The standard adult dosage is 30 mg two to three times daily (one 45 mg capsule provides a 30 mg dose of Idebenone).
Take the last daily dose before 5 p.m. to reduce the risk of sleep onset disturbances.
The typical treatment course is 1.5 to 2 months.
If clinically required, repeat treatment with two to three courses per year, as determined by a physician.
Do not exceed the prescribed dosage or duration of treatment.
Swallow the capsule whole; do not chew or crush.
Adverse Reactions
From the central nervous system: sleep onset disturbance, mental agitation, headache.
Other: dyspepsia, allergic reactions.
Contraindications
Chronic renal failure, hypersensitivity to the active substance.
Use in Pregnancy and Lactation
Use with caution during pregnancy and lactation.
Use in Renal Impairment
Contraindicated in chronic renal failure.
Special Precautions
Effect on the ability to drive vehicles and machinery
Do not take while working for vehicle drivers and patients whose profession requires high concentration and rapid psychomotor reactions.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer